Solco Biomedical Balance Sheet Health
Financial Health criteria checks 4/6
Solco Biomedical has a total shareholder equity of ₩19.5B and total debt of ₩28.0B, which brings its debt-to-equity ratio to 143.5%. Its total assets and total liabilities are ₩58.3B and ₩38.8B respectively.
Key information
143.5%
Debt to equity ratio
₩28.02b
Debt
Interest coverage ratio | n/a |
Cash | ₩10.47b |
Equity | ₩19.53b |
Total liabilities | ₩38.76b |
Total assets | ₩58.29b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A043100's short term assets (₩31.9B) exceed its short term liabilities (₩27.0B).
Long Term Liabilities: A043100's short term assets (₩31.9B) exceed its long term liabilities (₩11.8B).
Debt to Equity History and Analysis
Debt Level: A043100's net debt to equity ratio (89.9%) is considered high.
Reducing Debt: A043100's debt to equity ratio has increased from 32.8% to 143.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A043100 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A043100 has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 11% each year.